Together, these studies define the clinico-pathological hallmarks of SCLC transformation: retention of the initiating EGFR mutation, acquisition of neuroendocrine morphology and markers, frequent loss of T790M at transformation, and enrichment for co-alterations in TP53 and RB1. This evidence concerns the gene EGFR and small cell lung carcinoma.